<DOC>
	<DOCNO>NCT00031551</DOCNO>
	<brief_summary>This study consist two part : pilot study main study . The purpose pilot study demonstrate effectiveness plan laboratory technique ass TNF-alpha gene expression unstimulated saliva , plasma , mucosal epithelial cell patient chemotherapy-related stomatitis . Main Study Description : Stomatitis define inflammation mucous membrane oral cavity oropharynx characterize tissue erythema , edema , atrophy , often progress ulceration . Stomatitis biologically complex , multifactorial , cancer treatment-related oral condition experience many oncology patient , often lead cascade negative sequela include oropharyngeal pain , critical treatment alteration cessation , decrease quality life . The optimal treatment strategy stomatitis establish . There critical need examine pathogenesis evaluate intervention stomatitis relate acute oropharyngeal pain randomize controlled clinical trial set use valid reliable stomatitis assessment tool advance science cancer treatment-related oral toxicity improve patient care . Therefore , purpose randomize controlled clinical trial elucidate role inflammation stomatitis test effect novel tumor necrosis factor ( TNF ) fusion protein etanercept , ( Enbrel , Immunex Corporation , Seattle , WA ) incidence severity stomatitis . The action fusion protein , bind specifically TNF prevent interaction cellular receptor alter inflammatory cascade , may provide insight role inflammation stomatitis . An etanercept effect define prevention amelioration stomatitis acute oropharyngeal pain and/or change level tissue mediator . If stomatitis primarily consequence mucosal inflammatory response , hypothesize oral condition responsive binding TNF ( alpha ) . Elaboration role inflammatory cell signal associate stomatitis effect TNF ( alpha ) may elucidate mechanism related pathogenesis stomatitis mucosal condition . Patients schedule receive autologous allogenic peripheral blood stem cell bone marrow transplant invite participate study regularly schedule pre-treatment visit . Written inform consent obtain participant . Patients randomize receive either etanercept mouthwash placebo , administer protocol schedule . Stomatitis oropharyngeal pain measure baseline specify post-chemotherapy time point correspond predict stomatitis onset , peak , heal time course . TNF ( alpha ) level buccal mucosa , analyzed reverse transcriptase polymerase chain reaction technique , blood level pro-inflammatory cytokine , growth factor , inflammatory mediator also measure baseline specify post-chemotherapy time point correspond predict stomatitis onset , peak , heal time course .</brief_summary>
	<brief_title>Evaluation Efficacy Mechanisms Antiinflammatory Intervention Chemotherapy Related Mucosal Injury</brief_title>
	<detailed_description>This study consist two part : pilot study main study . The purpose pilot study demonstrate effectiveness plan laboratory technique ass TNF-alpha gene expression unstimulated saliva , plasma , mucosal epithelial cell patient chemotherapy-related stomatitis . Main Study Description : Stomatitis define inflammation mucous membrane oral cavity oropharynx characterize tissue erythema , edema , atrophy , often progress ulceration . Stomatitis biologically complex , multifactorial , cancer treatment-related oral condition experience many oncology patient , often lead cascade negative sequela include oropharyngeal pain , critical treatment alteration cessation , decrease quality life . The optimal treatment strategy stomatitis establish . There critical need examine pathogenesis evaluate intervention stomatitis relate acute oropharyngeal pain randomize controlled clinical trial set use valid reliable stomatitis assessment tool advance science cancer treatment-related oral toxicity improve patient care . Therefore , purpose randomize controlled clinical trial elucidate role inflammation stomatitis test effect novel tumor necrosis factor ( TNF ) fusion protein etanercept , ( Enbrel ) ( Registered Trademark ) , Immunex Corporation , Seattle , WA ) incidence severity stomatitis . The action fusion protein , bind specifically TNF prevent interaction cellular receptor alter inflammatory cascade , may provide insight role inflammation stomatitis . An etanercept effect define prevention amelioration stomatitis acute oropharyngeal pain and/or change level tissue mediator . If stomatitis primarily consequence mucosal inflammatory response , hypothesize oral condition responsive binding TNFa . Elaboration role inflammatory cell signal associate stomatitis effect TNFa may elucidate mechanism related pathogenesis stomatitis mucosal condition . Patients schedule receive autologous allogeneic peripheral blood stem cell bone marrow transplant invite participate study regularly schedule pre-treatment visit . Written inform consent obtain participant . Patients randomize receive either etanercept 2.5mg 20cc mouthwash placebo 20cc mouthwash , administer protocol schedule . Stomatitis oropharyngeal pain measure baseline specify post-chemotherapy time point correspond predict stomatitis onset , peak , heal time course . TNFa level buccal mucosa , analyze real time polymerase chain reaction technique , blood level pro-inflammatory cytokine , growth factor , inflammatory mediator also measure baseline specify post-chemotherapy time point correspond predict stomatitis onset , peak , heal time course .</detailed_description>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Male female oncology patient enrol participate stomatogenic autologous allogeneic PBSCT/BMT protocol , willing participate study concurrently 2 . Able understand sign protocol consent assent 3 . Age 16 year old EXCLUSION CRITERIA : 1 . Pregnant lactating female 2 . Unable follow oral rinsing direction 3 . Intubation 4 . Chronic use medication confound assessment inflammatory response ( nonsteroidal antiinflammatory drug , antihistamine , steroid exception decadron commonly use antiemetic PBSCT/BMT setting ) 5 . Preexisting oral infection upper respiratory infection might maximize possibility infection sepsis contribute drugrelated adverse event 6 . Known hypersensitivity allergic reaction etanercept</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Stomatitis</keyword>
	<keyword>Oropharyngeal pain</keyword>
	<keyword>TNF</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cancer</keyword>
	<keyword>Oral cavity</keyword>
	<keyword>Oral mucous membrane</keyword>
	<keyword>Randomized control clinical trial</keyword>
	<keyword>Inflammation</keyword>
</DOC>